Resistance mechanisms of novel ALK inhibitors
| Project/Area Number |
24790798
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | ALK陽性肺癌 / アレクチニブ / 薬剤耐性 / 国際情報交換 |
|---|
| Research Abstract |
Mechanisms of resistance with novel ALK tyrosine kinase, alectinib were investigated. H3122, EML4-ALK positive lung cancer cell line were treated with alectinib and showed resistance. These cell lines showed EGFR phosphorylation and MET signaling activation.
Combination therapy with EGFR tyrosine kinase inhibitor or MET inhibitor were effective for the treatment of H3122 alectinib resistance mouse xenograft model.
|
Report
(3 results)
Research Products
(3 results)
